Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Spigel, D.R.; Faivre-Finn, C.; Gray, J.E.; Vicente, D.; Planchard, D.; Paz-Ares, L.; Vansteenkiste, J.F.; Garassino, M.C.; Hui, R.; Quantin, X.; et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. J. Clin. Oncol. 2022, 40, 1301–1311. [Google Scholar] [CrossRef] [PubMed]
- Bruni, A.; Scotti, V.; Borghetti, P.; Vagge, S.; Cozzi, S.; D’Angelo, E.; Levra, N.G.; Fozza, A.; Taraborrelli, M.; Piperno, G.; et al. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer. Front. Oncol. 2021, 11, 744956. [Google Scholar] [CrossRef] [PubMed]
- Patel, S.; Zhao, S.; Wei, L.; Li, M.; Bertino, E.; Presley, C.; Welliver, M.; Haglund, K.; Palmer, J.; Arnett, A.; et al. Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation. J. Thorac. Oncol. 2021, 16, S363–S364. [Google Scholar] [CrossRef]
- Le Pechoux, C.; Pourel, N.; Barlesi, F.; Lerouge, D.; Antoni, D.; Lamezec, B.; Nestle, U.; Boisselier, P.; Dansin, E.; Paumier, A.; et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): An open-label, randomised, phase 3 trial. Lancet Oncol. 2022, 23, 104–114. [Google Scholar] [CrossRef] [PubMed]
- Shimamura, S.; Saiki, M.; Ide, S.; Masuda, K.; Uchida, Y.; Sogami, Y.; Kasai, K.; Inoue, T.; Ishihara, H. Significant therapeutic effectiveness of durvalumab after chemoradiotherapy for a patient with post-operative recurrent pulmonary pleomorphic carcinoma. Respirol. Case Rep. 2021, 9, e00781. [Google Scholar] [CrossRef] [PubMed]
- Huber, R.M. Disease progression in non-small cell lung cancer on immune-checkpoint inhibition, what are the options? Precis. Cancer Med. 2019, 2, 13. [Google Scholar] [CrossRef]
- Fuloria, S.; Subramaniyan, V.; Karupiah, S.; Kumari, U.; Sathasivam, K.; Meenakshi, D.; Wu, Y.; Sekar, M.; Chitranshi, N.; Malviya, R.; et al. Comprehensive Review of Methodology to Detect Reactive Oxygen Species (ROS) in Mammalian Species and Establish Its Relationship with Antioxidants and Cancer. Antioxidants 2021, 10, 128. [Google Scholar] [CrossRef] [PubMed]
- Subramaniyan, V.; Fuloria, S.; Gupta, G.; Kumar, D.H.; Sekar, M.; Sathasivam, K.V.; Sudhakar, K.; Alharbi, K.S.; Al-Malki, W.H.; Afzal, O.; et al. A review on epidermal growth factor receptor’s role in breast and non-small cell lung cancer. Chem. Interact. 2021, 351, 109735. [Google Scholar] [CrossRef] [PubMed]
- Felip, E.; Altorki, N.; Zhou, C.; Csőszi, T.; Vynnychenko, I.; Goloborodko, O.; Luft, A.; Akopov, A.; Martinez-Marti, A.; Kenmotsu, H.; et al. IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial. Lancet 2021, 398, 1344–1357. [Google Scholar] [CrossRef] [PubMed]
- Borghetti, P.; Imbrescia, J.; Volpi, G.; Scotti, V.; Aquilano, M.; Bruni, A.; Franceschini, D.; Ursino, S.; Ciammella, P.; Piperno, G.; et al. Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC. Radiat. Oncol. 2022, 17, 124. [Google Scholar] [CrossRef] [PubMed]
- Terada, Y.; Isaka, M.; Harada, H.; Konno, H.; Kojima, H.; Mizuno, T.; Murayama, S.; Takahashi, T.; Ohde, Y. Radiotherapy for local recurrence of non-small-cell lung cancer after lobectomy and lymph node dissection can local recurrence be radically cured by radiation? Jpn. J. Clin. Oncol. 2020, 50, 425–433. [Google Scholar] [CrossRef] [PubMed]
- Senan, S.; Özgüroğlu, M.; Daniel, D.; Villegas, A.; Vicente, D.; Murakami, S.; Hui, R.; Faivre-Finn, C.; Paz-Ares, L.; Wu, Y.; et al. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: An exploratory analysis from the PACIFIC trial. ESMO Open 2022, 7, 100410. [Google Scholar] [CrossRef] [PubMed]
- Brooks, E.D.; Verma, V.; Senan, S.; De Baere, T.; Lu, S.; Brunelli, A.; Chang, J.Y.; International Association for the Study of Lung Cancer Advanced Radiation Technology Committee. Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC. J. Thorac. Oncol. 2019, 15, 176–189. [Google Scholar] [CrossRef] [PubMed]
- Brooks, E.D.; Sun, B.; Feng, L.; Verma, V.; Zhao, L.; Gomez, D.R.; Liao, Z.; Jeter, M.; O’Reilly, M.; Welsh, J.W.; et al. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Netw. Open 2018, 1, e181390. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chicas-Sett, R.; Zafra, J.; Rodriguez-Abreu, D.; Castilla-Martinez, J.; Benitez, G.; Salas, B.; Hernandez, S.; Lloret, M.; Onieva, J.L.; Barragan, I.; et al. Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study. Int. J. Radiat. Oncol. 2022, 114, 655–665. [Google Scholar] [CrossRef] [PubMed]
- Scoccianti, S.; Olmetto, E.; Pinzi, V.; Osti, M.F.; Di Franco, R.; Caini, S.; Anselmo, P.; Matteucci, P.; Franceschini, D.; Mantovani, C.; et al. Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: Results from a multicentric retrospective study on behalf of AIRO. Neuro-Oncol. 2021, 23, 1750–1764. [Google Scholar] [CrossRef] [PubMed]
- Kishi, N.; Matsuo, Y.; Shintani, T.; Ogura, M.; Mitsuyoshi, T.; Araki, N.; Fujii, K.; Okumura, S.; Nakamatsu, K.; Kishi, T.; et al. Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer. J. Radiat. Res. 2022, rrac057. [Google Scholar] [CrossRef] [PubMed]
- Mooradian, M.J.; Allen, A.; Cai, L. 100P SPOTLIGHT Real-world study: Patients characteristics and treatment patterns in patients with unresectable stage III NSLCL receiving durvalumab after chemoradiotherapy. Ann. Oncol. 2021, 32, S1417–S1418. [Google Scholar] [CrossRef]
- Taugner, J.; Kasmann, L.; Chukwuka, E.; Rühle, A.; Tufman, A.; Reinmuth, N.; Duell, T.; Belka, C.; Manapov, F. Real-world analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. Real-world analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. Investig. New Drugs 2021, 39, 1189–1196. [Google Scholar]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bruni, A.; Bertolini, F.; D’Angelo, E.; Guaitoli, G.; Imbrescia, J.; Cappelli, A.; Guidi, G.; Stefani, A.; Dominici, M.; Lohr, F. Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature. Int. J. Mol. Sci. 2023, 24, 1892. https://doi.org/10.3390/ijms24031892
Bruni A, Bertolini F, D’Angelo E, Guaitoli G, Imbrescia J, Cappelli A, Guidi G, Stefani A, Dominici M, Lohr F. Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature. International Journal of Molecular Sciences. 2023; 24(3):1892. https://doi.org/10.3390/ijms24031892
Chicago/Turabian StyleBruni, Alessio, Federica Bertolini, Elisa D’Angelo, Giorgia Guaitoli, Jessica Imbrescia, Anna Cappelli, Gabriele Guidi, Alessandro Stefani, Massimo Dominici, and Frank Lohr. 2023. "Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature" International Journal of Molecular Sciences 24, no. 3: 1892. https://doi.org/10.3390/ijms24031892